ReNeuron Group Plc (LON:RENE) has presented encouraging new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London.
Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
Dr Randolph Corteling, ReNeuron’s Head of Research, said the data being presented at the ISCT 2017 conference represented key advances in the development of its programme.
CLICK HERE: For a daily round-up of all the Proactive news
On one poster, ReNeuron and its academic collaborators reported a significant increase in large-scale purifying CTX-derived exosomes while preserving their potential therapeutic attributes.
Better purification methods are needed to remove protein and DNA-based impurities from the exosomes to produce them at commercially relevant scale.
In a second poster presentation, ReNeuron highlighted work undertaken to guarantee consistency and control during manufacture.
“The application of robust characterisation and purification methods to ReNeuron's exosome populations will support future development of the Company's exosome-based therapeutic candidates across multiple potential disease indications, the initial disease target being cancer,” said the company.
The data was presented at the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting in London.